TScan Therapeutics, Inc.
TCRX Nasdaq
SEC CIK 1783328
Follow TScan Therapeutics
Weekly email: filings, results
Revenue, last quarter
$586K
−76.7% vs same quarter last year
Net income
−$33.1M
+7.4% vs same quarter last year
EPS, diluted
−$0.25
+10.7% vs same quarter last year
Operating cash flow
−$27.1M
+16.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $10.3M | −$129.8M |
| FY24 | $2.8M | −$127.5M |
| FY23 | $21M | −$89.2M |
| FY22 | $13.5M | −$66.2M |
| FY21 | $10.1M | −$48.6M |
| FY20 | $1.1M | −$26.1M |
| FY19 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −1315.4% | −1256.8% |
| FY24 | −4787.7% | −4527.7% |
| FY23 | −444% | −423.9% |
| FY22 | −492.3% | −489.3% |
| FY21 | −479.6% | −479.5% |
| FY20 | −2417.8% | −2408% |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$139.7M |
| FY24 | −$114.6M |
| FY23 | −$64.5M |
| FY22 | −$70.7M |
| FY21 | −$58.6M |
| FY20 | −$7.3M |
| FY19 | - |
- TScan Therapeutics
- Healthcare median
Show the numbers
| Year | TScan Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −1256.8% | −30.6% |
| FY24 | −4527.7% | −47% |
| FY23 | −423.9% | −58% |
| FY22 | −489.3% | −80.4% |
| FY21 | −479.5% | −71.8% |
| FY20 | −2408% | −62.2% |
| FY19 | - | −46.2% |